Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Bridging Therapy with Loncastuximab Tesirine and Rituximab for the Treatment of Relapsed/Refractory Large B-cell Lymphoma in Patients Undergoing CD19 CAR T-cell Therapy

Trial Status: active

This phase II trial studies how well bridging therapy with loncastuximab tesirine and rituximab (lonca-R) works in treating patients that are undergoing standard of care (SOC) CD19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). CD19 CAR T-cell therapy is a treatment that uses T-cells that have been engineered to contain a CAR that specifically targets the CD19 antigen. Bridging therapy is often given before CAR T-cell therapy to help transition the patient to the CAR T-cell therapy or to maintain their health or status until they are a candidate for the CAR T-cell therapy. Loncastuximab tesirine is a monoclonal antibody, called loncastuximab, linked to a drug, called pyrrolobenzodiazepine (PBD). Loncastuximab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers PBD to kill them. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving bridging therapy with lonca-R may be effective in treating patients undergoing SOC CD19 CAR T-cell therapy for relapsed/refractory (R/R) large B-cell lymphoma.